Filtros de búsqueda

Lista de obras de

2226. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series

A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

artículo científico publicado en 2010

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

artículo científico publicado en 2020

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

artículo científico publicado en 2011

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

artículo científico publicado en 2012

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

artículo científico publicado en 2012

A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases

artículo científico publicado en 2013

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

artículo científico publicado en 2013

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

artículo científico publicado en 2014

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

artículo científico publicado en 2009

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

artículo científico publicado en 2011

A pilot study of temsirolimus and body composition

artículo científico publicado en 2013

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

artículo científico publicado en 2015

Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment

artículo científico publicado en 2014

Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center

artículo científico publicado en 2013

Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience

artículo científico publicado en 2012

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

artículo científico publicado en 2014

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

artículo científico publicado en 2016

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

artículo científico publicado en 2014

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

artículo científico publicado en 2014

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

scientific article published on 22 August 2019

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer

artículo científico publicado en 2017

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

artículo científico publicado en 2014

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

artículo científico publicado en 2016

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

artículo científico

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

artículo científico publicado en 2015

BRAF mutations in advanced cancers: clinical characteristics and outcomes

artículo científico publicado en 2011

Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit

artículo científico publicado en 2013

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study.

artículo científico publicado en 2015

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

artículo científico publicado en 2016

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors ⬇️

artículo científico publicado en 2014

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies

artículo científico publicado en 2012

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience

artículo científico publicado en 2015

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials

artículo científico publicado en 2018

Characteristics and survival of patients with advanced cancer and p53 mutations

artículo científico publicado en 2014

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience

artículo científico publicado en 2014

Clinical next generation sequencing to identify actionable aberrations in a phase I program

artículo científico publicado en 2015

Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience

artículo científico publicado en 2010

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations

artículo científico publicado en 2013

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience

artículo científico publicado en 2016

Cutaneous Castleman disease ⬇️

artículo científico publicado el 26 de abril de 2012

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors

scientific article published on 01 April 2020

Developmental therapeutics for myelodysplastic syndromes

artículo científico publicado en 2006

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

scientific article published on 12 April 2022

Dodging a dogma: is treating beyond progression beneficial? ⬇️

artículo científico publicado el 27 de febrero de 2013

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

artículo científico publicado en 2015

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

artículo científico publicado en 2014

Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer

artículo científico publicado en 2013

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

artículo científico publicado en 2014

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

artículo científico publicado en 2014

Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance

artículo científico publicado en 2011

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

artículo científico publicado en 2015

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

artículo científico publicado en 2020

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies

artículo científico publicado en 2016

Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy

artículo científico publicado en 2014

Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells

artículo científico publicado en 2013

Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies

artículo científico publicado en 2013

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials

artículo científico publicado en 2015

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

artículo científico publicado en 2014

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

scientific article published on 03 December 2019

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

artículo científico publicado en 2020

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

artículo científico publicado en 2017

Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model

artículo científico publicado en 2017

Genomics, morphoproteomics, and treatment patterns of alveolar soft part sarcoma patients and response to multiple experimental therapies

scientific article published on 03 March 2020

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications

artículo científico publicado en 2013

Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience

artículo científico publicado en 2013

Hepatocellular carcinoma: Where there is unmet need

artículo científico publicado en 2015

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma

artículo científico publicado en 2016

Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience

artículo científico publicado en 2016

Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response

scientific article published on 25 March 2014

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies

artículo científico publicado en 2011

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

artículo científico publicado en 2012

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

artículo científico publicado en 2017

Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis

artículo científico publicado en 2016

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

artículo científico publicado en 2016

Juice plus or toxicity plus

artículo científico publicado en 2010

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

artículo científico publicado en 2012

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

artículo científico publicado en 2017

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

artículo científico publicado en 2014

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

artículo científico publicado en 2013

Metformin: an old drug with new potential

artículo científico publicado en 2013

Methotrexate-induced status epilepticus

artículo científico publicado en 2005

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

artículo científico publicado en 2013

Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes

artículo científico publicado en 2020

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

artículo científico publicado en 2015

Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors

artículo científico publicado en 2014

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines

artículo científico publicado en 2015

Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program

artículo científico publicado en 2011

Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience

artículo científico publicado en 2012

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

artículo científico publicado en 2014

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic

artículo científico publicado en 2011

Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program

artículo científico publicado en 2014

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

artículo científico publicado en 2016

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

artículo científico publicado en 2017

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience

artículo científico publicado en 2011

Overcoming platinum resistance through the use of a copper-lowering agent

artículo científico publicado en 2012

Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials ⬇️

artículo científico publicado el 30 de abril de 2013

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy

scientific article published on May 2013

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

artículo científico publicado en 2012

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

artículo científico publicado en 2012

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

artículo científico publicado en 2011

PIK3CA mutations in advanced cancers: characteristics and outcomes

artículo científico publicado en 2012

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

artículo científico publicado en 2011

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment

artículo científico publicado en 2010

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

artículo científico publicado en 2014

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

artículo científico publicado en 2012

Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience

artículo científico publicado en 2010

Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

artículo científico publicado en 2017

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

artículo científico publicado en 2021

Phase 2 study of pembrolizumab in patients with advanced rare cancers

scientific article published on 01 March 2020

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors

artículo científico publicado en 2011

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma ⬇️

artículo científico publicado en 2015

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

artículo científico publicado en 2016

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

artículo científico publicado en 2014

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

artículo científico publicado en 2017

Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement

artículo científico publicado en 2010

Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement

artículo científico publicado en 2010

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

artículo científico publicado en 2016

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

artículo científico publicado en 2013

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

artículo científico publicado en 2013

Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience

artículo científico publicado en 2011

Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2009

Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2010

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

artículo científico publicado en 2015

Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

artículo científico publicado en 2016

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

artículo científico publicado en 2013

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

artículo científico publicado en 2016

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

artículo científico publicado en 2010

Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients

artículo científico publicado en 2017

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors

artículo científico publicado en 2013

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

artículo científico publicado en 2014

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

artículo científico publicado en 2015

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity

artículo científico publicado en 2012

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

artículo científico publicado en 2017

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies

artículo científico publicado en 2009

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

artículo científico publicado en 2011

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity

artículo científico publicado en 2011

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

artículo científico publicado en 2015

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses

scientific article published on 28 October 2019

Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit

artículo científico publicado en 2016

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

artículo científico publicado en 2020

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

artículo científico publicado en 2018

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic

Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience

artículo científico publicado en 2011

Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis

artículo científico publicado en 2020

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

scientific article published on 10 October 2019

Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors

artículo científico publicado en 2017

Retreatment after secondary resistance or mixed response: a pilot study

artículo científico publicado en 2013

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population

artículo científico publicado en 2013

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

scientific article published on 04 September 2020

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

artículo científico publicado en 2020

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

artículo científico publicado en 2016

Safety, feasibility and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial.

artículo científico publicado en 2015

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

artículo científico publicado en 2017

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials

artículo científico publicado en 2016

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges

scientific article published on 01 October 2020

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges

scientific article published on 01 December 2020

Strategies for combining immunotherapy with radiation for anticancer therapy

artículo científico publicado en 2015

Strategies for improving the management of immune-related adverse events

scientific article published on 01 December 2020

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

artículo científico publicado en 2012

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2009

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience

artículo científico publicado en 2016

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic

artículo científico publicado en 2014

T-cell agonists in cancer immunotherapy

artículo científico publicado en 2020

TAS-106: preclinical, clinical and beyond

artículo científico

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

artículo científico publicado en 2016

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

artículo científico publicado en 2013

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

artículo científico publicado en 2014

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures

artículo científico publicado en 2011

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials

artículo científico publicado en 2013

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

artículo científico publicado en 2014

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

artículo científico publicado en 2015

The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab

artículo científico publicado en 2015

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

artículo científico publicado en 2021

Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses

artículo científico publicado en 2013

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents

artículo científico publicado en 2014

Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors.

artículo científico publicado en 2015

Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root

artículo científico publicado en 2004

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials

artículo científico publicado en 2016

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center

artículo científico publicado en 2011

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial

artículo científico publicado en 2013

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda